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Context
Despite advances in theoretical knowledge, many large prospective trials of novel therapies in trauma and critical care provide disappointing results. This may, in part, be because the wrong patients are included (i.e. those with very high probability of death) or because the therapy may not affect survival but still improve outcome. The early termination of two recent trials has highlighted two main problems with studies in critically ill patients: firstly, it may not be ethical to recruit patients to these trials unless the subgroups who may benefit can be more clearly defined; secondly large amounts of resources are wasted on failed trials. It is therefore very important to understand the nature of the disease, patient disparity, and the effect of the distribution of the probability of survival when testing hypotheses.
Significant findings
Trauma patients (those retrieved by SAMU, Paris, France) had a bimodal distribution of probability of survival (Ps), with peaks at Ps <0.1 and Ps >0.9. The heterogeneity in the probability of survival had a marked effect on the study size required, depending on whether the study was powered for the percentage of survivors or the individual chances of survival (e.g. for a drug that increases the probability of survival by 20% n = 63,202 versus n= 2848 respectively). This discrepancy occurred with J shaped distributions to a lesser extent. This could be overcome by identifying factors that place patients in an intermediate Ps group.
Comments
This paper is an interesting piece of work, which highlights some of the pitfalls of study design in intensive care. It should be read by anyone contemplating a major study of outcomes in the critically ill. The overestimation of power is most likely to occur with a bimodal distribution of Ps as in this case and would be less marked with other distributions. It would suggest that we should only recruit patients with similar Ps, rather than taking a mean value across the study population
